Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Long term and recent down trendline, broken above, price target 5368, although UBS recently had a target of 5500.
There is however overhead supply from previous trading , at 5000, which may provide resistance , from sellers.
Recent price action implies compression, with converging lines of support and resistance, which usually means a reasonably fast movement on a breakout. DYOR.
This appears to be a Ft 100 share .
https://www.fool.co.uk/2023/10/09/down-33-is-the-croda-share-price-now-too-good-to-miss
Not only AIM with huge swings .
Bought this 24th November 2020 @ 5900p sold it 27th July 2021 @ 8200p
Not looked since
13th December 2021 topped at 10,410p wow
16th October 2023 fell back below my buy to 4070p wow.
No wonder 2021 saw such highs .
Bullish price pivot breakout today. Although bollinger bands on hourly chart suggest price retracement, likely, and possibly to price range of 5778-5818, within 2 days , this forthcoming Thursday. There is a lot of overhead supply, previous trading at higher levels to slow down any future sp, rise above 6000. So this is a weak buy at best.
I have independently come to the same conclusion of 45 pounds, that you advised.
Looking at the long term chart, this is a buy at 45 pounds.
Plenty of opportunity for the SP to fall further! We are back to levels last seen in 2020 and I would not be in the least surprised if the price falls to test recent lows.
No point making any hasty decision.
Oversold
Not great, no!
Where could it settle now over the next few months?
Update today is not great. Probably in for a caning today, but markets may react differently
https://uk.finance.yahoo.com/news/uks-croda-annual-profit-beats-075223800.html
Croda posted a rise in full-year sales and profit as it hailed a strong performance in Asia, Western Europe and Latin America, and growth across consumer care and life sciences.
In the year to the end of December 2022, pre-tax profit rose 89.6% to £780m, with sales up 10.6% to £2.1bn.
Chief executive Steve Foots said: "2022 has been a milestone year for Croda as we continued our transition to a pure play consumer care and life sciences business, evolving our portfolio to be more closely aligned to the emerging megatrends driving our markets.
"For the first time, we delivered over £2 billion in sales and £500 million in adjusted operating profit, reflecting progress across all areas of our business. Consumer care is increasingly resilient, supported by encouraging growth in our F&F business, whilst life sciences has built on an exceptional prior year, with an exciting project pipeline in pharma and a stand-out performance in crop protection."
A_S I'm in the same boat, but I am thinking of adding to my holding, but my wait until Liz Truss makes another financial faux pas!
The Sunday Times has rated CRDA as a buy in the finance pages.
For myself, 2022 has been a dreadful year with no hiding places. Few holdings are in positive territory and most are well under water. The problem that investors face is that there are so many really top notch investments that are at their lows.
I have now sold these after holding for 12 months.
I made a disappointing loss of 19%.
I was up 22% in December but in then fell 44% before recovering a little.
Good to see it back over £70, up 20% over the last month.
No. 200 day SMA is £81.
gggggg...sorry i am getting mixed up with johnson matthey where they closed their battery division(...re strategy)
What's wrong with their strategy?
Croda ..best riser on ftse 100 yesterday...market woes and company strategy has pushed down price
Nice to see it back over £60.
A bit premature, down 11% in the last month, momentum investing out of favour recently.